Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

Blood (2016) 128 (22): 151.

https://doi.org/10.1182/blood.V128.22.151.151

Published: 2016

Journal Articles

In MDS Targeted Deep Sequencing of CD34 + Blood Cells but Not Peripheral Blood Mononuclear Cells Give Results Which Are Representative for Bone Marrow

Roman Martin, PhD, Laura Palomo, MSc, Christina Ganster, PhD, Pamela Acha, Sascha Dierks, PhD, Mar Mallo, PhD, Vera Adema, Francisco Fuster-Tormo, MSc, Paula Gomez-Marzo, MSc, Nuria De Haro, Neus Solanes, Lurdes Zamora, PhD, Blanca Xicoy, MD, Arkadiusz Kominowski, Martin Stromburg, Alina Brockmann, Lorenz H. Truemper, MD PhD, Francesc Sole, PhD, Detlef Haase, MD

Blood (2016) 128 (22): 2383.

https://doi.org/10.1182/blood.V128.22.2383.2383

Published: 2016

Journal Articles

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Roxana Schaab, Christina Ganster, PhD, Sascha Dierks, PhD, Katayoon Shirneshan, PhD, Marc Talló Parra, Roman Martin, PhD, Ulrich Germing, Uwe Platzbecker, MD, Frank Lange, MD, Nicolaus Kroeger, MD, Konstanze Döhner, MD, Bertram Glass, MD, Maike Nickelsen, MD, Reingard Stuhlmann, MD, Lorenz H. Truemper, MD, Julie Schanz, MD, Ulrike Bacher, MD, Detlef Haase, MD

Blood (2016) 128 (22): 2001.

https://doi.org/10.1182/blood.V128.22.2001.2001

Published: 2016

Journal Articles

Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R- CHOP

Karin Hohloch, PD Dr., Bettina Altmann, Michael Pfreundschuh, MD, Markus Loeffler, Prof., Norbert Schmitz, MD, Marita Ziepert, PhD, Lorenz H. Truemper, MD PhD

Blood (2015) 126 (23): 1509.

https://doi.org/10.1182/blood.V126.23.1509.1509

Published: 2015

Journal Articles

Identification of Blut, a Novel Long-Noncoding RNA Differentially Expressed in Burkitt Lymphoma

Blood (2015) 126 (23): 3875.

https://doi.org/10.1182/blood.V126.23.3875.3875

Published: 2015

Journal Articles

Liposomal Formulation of Vincristine Allows for Doubling the Dose Compared to Conventional Vincristine: Results of the First Futility Analysis of the OPTIMAL>60 Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Sascha Duecker, Viola Poeschel, Anne Wolf, MD, Gerhard Held, MD, Niels Murawski, MD, Carsten Zwick, MD, Mathias Haenel, MD, Andreas Viardot, Lorenz H. Truemper, MD PhD, Marita Ziepert, Michael Pfreundschuh

Blood (2014) 124 (21): 4420.

https://doi.org/10.1182/blood.V124.21.4420.4420

Published: 2014

Journal Articles

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Bertram Glass, MD, Anke Goerlitz, Sebastian Pfeiffer, Maike Nickelsen, MD, Andreas Huettmann, MD, Justin Hasenkamp, MD, Lorenz H. Truemper, MD PhD, Martin Dreyling, Michael G Kiehl, MD, Hans Salwender, MD, Norbert Schmitz, MD

Blood (2014) 124 (21): 1754.

https://doi.org/10.1182/blood.V124.21.1754.1754

Published: 2014

Journal Articles

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Justin Hasenkamp, MD, Georg Hess, MD, Bernd Hertenstein, MD, Mathias Witzens-Harig, MD, Lutz Uharek, MD, Martin Gramatzki, MD, Michael Pfreundschuh, Gerald Wulf, MD, Lorenz H. Truemper, MD PhD, Norbert Schmitz, MD, Bertram Glass, MD

Blood (2014) 124 (21): 3986.

https://doi.org/10.1182/blood.V124.21.3986.3986

Published: 2014

Journal Articles

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Bertram Glass, MD, PhD, Justin Hasenkamp, MD, Anke Goerlitz, Peter Dreger, Joerg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3379.

https://doi.org/10.1182/blood.V114.22.3379.3379

Published: 2009

Journal Articles

Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network.

Wojciech Jurczak, MD, Aleksander B. Skotnicki, MD, Andrzej Deptala, MD, Christine Windemuth-Kieselbach, PhD, Michael Lorsbach, Angelika Bischof Delaloye, MD, Suh Cheolwon, MD, Pier Luigi Zinzani, MD, Roberto Cacchione, MD, Werner Linkesch, MD, Francesco d'Amore, MD, Lorenz H. Truemper, MD

Blood (2009) 114 (22): 3746.

https://doi.org/10.1182/blood.V114.22.3746.3746

Published: 2009

Journal Articles

Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.

Bertram Glass, MD, PhD, Andrea Borgerding, Marita Ziepert, Maike Nickelsen, Markus Loeffler, Prof., Michael Pfreundschuh, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3714.

https://doi.org/10.1182/blood.V114.22.3714.3714

Published: 2009

Journal Articles

MERIT Study – “Multicenter Evaluation of Patient- and Lesion-Specific Prognostic Factors for RadioImmunoTherapy with 90 yttrium-Labeled Anti-CD20 in Follicular Non-Hodgkin's lymphoma”.

Aleksandar Grgic, MD, Ursula Nestle, MD, PhD, Elena Ballek, MD, Klemens Scheidhauer, MD, PhD, Cornelia Puskas, MD, Jochem Koenig, PhD, Karin Hohloch, MD, Joerg Schubert, MD, Lorenz H. Truemper, Carl-Martin Kirsch, MD, PhD

Blood (2009) 114 (22): 4792.

https://doi.org/10.1182/blood.V114.22.4792.4792

Published: 2009

Journal Articles

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Martin H. Dreyling, MD, Eva Hoster, PhD, Achiel Van Hoof, Bernd Metzner, Christian Gisselbrecht, Michael Pfreundschuh, MD, PhD, Marcel Reiser, Lorenz H. Truemper, MD, PhD, Hjalmar Steinhauer, Jean-Michel Boiron, MD, PhD, Marc Boogaerts, MD, PhD, Vittorio Silingardi, J.C. Kluin- Nelemans, MD, PhD, Michael Unterhalt, Wolfgang Hiddemann

Blood (2008) 112 (11): 769.

https://doi.org/10.1182/blood.V112.11.769.769

Published: 2008

Journal Articles

Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network

Karin Hohloch, MD, P.L. Zinzani, M.D., Werner Linkesch, Jr., Andrzej Deptala, MD, PhD, Jurczak Wojciech, Cheolwon Suh, Michael Lorsbach, Christiane Windemuth-Kiesselbach, Lorenz H. Truemper

Blood (2008) 112 (11): 3064.

https://doi.org/10.1182/blood.V112.11.3064.3064

Published: 2008

Journal Articles

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Blood (2008) 112 (11): 2776.

https://doi.org/10.1182/blood.V112.11.2776.2776

Published: 2008

Journal Articles

Evidence for a Suppression of the Colony Forming Capacity of Erythroid Progenitors by Iron Overload in Patients with MDS

Julia Hartmann, Ursula Sinzig, Gerald Wulf, MD, PhD, Lorenz H. Truemper, MD, PhD, Friederike Braulke, MD, Frank Konietschke, Detlef Haase, MD, PhD

Blood (2008) 112 (11): 2694.

https://doi.org/10.1182/blood.V112.11.2694.2694

Published: 2008

Journal Articles

Analysing Circulating CD34+ Cells by FISH Is Representative for the Clone Size in Bone Marrow in MDS Patients Under Different Therapy Modalities

Friederike Braulke, MD, Julie Schanz, MD, Lorenz H. Truemper, MD, PhD, Detlef Haase, MD, PhD

Blood (2008) 112 (11): 2696.

https://doi.org/10.1182/blood.V112.11.2696.2696

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Juergen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz H. Truemper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 329.

https://doi.org/10.1182/blood.V112.11.329.329

Published: 2008

Journal Articles

Multikinase Inhibition by Sorafenib in B and T NHL Cell Lines: Increasing Cytostatic Efficacy after Prolonged Exposure

Bjoern Chapuy, Nikolai Schuelper, Elisabeth Kaehler, Lorenz H. Truemper, Gerald Wulf

Blood (2008) 112 (11): 4980.

https://doi.org/10.1182/blood.V112.11.4980.4980

Published: 2008

Journal Articles

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Anke Görlitz, Peter Dreger, MD, Jörg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 1974.

https://doi.org/10.1182/blood.V112.11.1974.1974

Published: 2008

NARROW

The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl

In MDS Targeted Deep Sequencing of CD34 + Blood Cells but Not Peripheral Blood Mononuclear Cells Give Results Which Are Representative for Bone Marrow

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R- CHOP

Identification of Blut, a Novel Long-Noncoding RNA Differentially Expressed in Burkitt Lymphoma

Liposomal Formulation of Vincristine Allows for Doubling the Dose Compared to Conventional Vincristine: Results of the First Futility Analysis of the OPTIMAL>60 Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Consolidation with Radioimmunotherapy May Prolong Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for Stem Cell Transplantation, An Analysis of the International RIT-Network.

Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.

MERIT Study – “Multicenter Evaluation of Patient- and Lesion-Specific Prognostic Factors for RadioImmunoTherapy with 90 yttrium-Labeled Anti-CD20 in Follicular Non-Hodgkin's lymphoma”.

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Evidence for a Suppression of the Colony Forming Capacity of Erythroid Progenitors by Iron Overload in Patients with MDS

Analysing Circulating CD34+ Cells by FISH Is Representative for the Clone Size in Bone Marrow in MDS Patients Under Different Therapy Modalities

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Multikinase Inhibition by Sorafenib in B and T NHL Cell Lines: Increasing Cytostatic Efficacy after Prolonged Exposure

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only